Construction method of gastric adenocarcinoma model

By constructing the LSL-KrasG12D/+;Tp53 R172H/+;Anxa10-Cre/+ mouse model and applying N-methyl-N-nitrosourea, combined with tamoxifen induction, a gastric adenocarcinoma model and cell line ST-YC19 were established, solving the problem that the existing model cannot accurately reflect the microenvironment of gastric adenocarcinoma, and achieving efficient gastric adenocarcinoma research and drug screening.

CN120501087AActive Publication Date: 2025-08-19BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202510998238.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-07-18
Publication Date
2025-08-19
Estimated Expiration
2045-07-18

AI Technical Summary

Technical Problem

The existing gastric cancer models cannot accurately reflect the microenvironmental characteristics of gastric adenocarcinoma. Traditional models such as PDX and CDX models cannot simulate the in situ tumor microenvironment, and the existing mouse gastric cancer cell lines cannot represent the characteristics of gastric adenocarcinoma, and there is a lack of suitable animal models and cell lines for gastric adenocarcinoma.

Method used

LSL-KrasG12D/+;Tp53 R172H/+;Anxa10-Cre/+ mouse models were constructed through mating and genetic manipulation, and N-methyl-N-nitrosourea was administered, combined with the knockout activator tamoxifen, to induce gastric adenocarcinoma formation, and then gastric adenocarcinoma cells were isolated and immortalized to establish the gastric adenocarcinoma cell line ST-YC19.

Benefits of technology

The constructed gastric adenocarcinoma model shortened the tumor-generating cycle to about 2.5 months, with a tumor-generating rate of 100%. The gastric adenocarcinoma cells have strong proliferation, invasion and migration ability, and are suitable for gastric adenocarcinoma research and drug screening.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120501087A_ABST
    Figure CN120501087A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biology, and particularly relates to a construction method of a gastric adenocarcinoma model. The method comprises the following steps: enabling an Anxa10-Cre / + animal or a filial generation of the Anxa10-Cre / + animal to react with LSL-KrasG12D / +; the method comprises the following steps: breeding a Tp53 R172H / + animal or a filial generation of the Tp53 R172H / + animal to obtain LSL-KrasG12D / +; tp53 R172H / < + >; anxa < 10 >-Cre / + animal; the method comprises the following steps of: adding LSL-KrasG12D / +; tp53 R172H / < + >; and N-methyl-N-nitrosourea is applied to an Anxa10-Cre / + animal. According to the method, the tumor formation period is shortened (about 2.5 months), the tumor formation rate is improved (100%), and the pathological type of the obtained gastric adenocarcinoma model is determined as adenocarcinoma.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and particularly relates to a method for constructing a gastric adenocarcinoma model. Background Art

[0002] Gastric cancer (GC) is one of the most common malignancies worldwide, ranking fifth in incidence and fourth in mortality as of 2020. In 2020 alone, over one million newly diagnosed cases and approximately 770,000 deaths were attributed to the disease. With the advent of precision diagnosis and treatment for GC, targeted therapies and immunotherapies are becoming mainstream treatments for GC, and a large amount of basic and translational research related to precision diagnosis and treatment for GC is underway. However, precision diagnosis and treatment requires more precise classification of GC, and the lack of animal models that can more accurately characterize the composition and function of the tumor microenvironment is a key issue. Classic GC models, including patient-derived tumor xenograft (PDX) models and cell-derived xenograft (CDX) models, are mostly implanted in the flank of immunodeficient mice and fail to reflect the microenvironmental characteristics of orthotopic GC tumors. While double-humanized immune mice, which use severely deficient mice to construct mouse models with humanized immune systems (such as NCG-hIL15) (Chinese patent document CN114786479A), can partially simulate the immune microenvironment, they suffer from low NK cell survival, which affects the accuracy of drug efficacy evaluation, is extremely costly, and lacks invasiveness. Currently, the only commercially available mouse gastric cancer cell line is the MFC gastric squamous cell carcinoma cell line, which accounts for only 0.04%-1% of gastric cancer patients and cannot reflect the characteristics of gastric adenocarcinoma, the pathological type of the vast majority of gastric cancer patients. Therefore, the establishment of a gastric adenocarcinoma model and the construction of a gastric adenocarcinoma cell line are urgently needed. Summary of the Invention

[0003] The first aspect of the present invention aims to provide a method for constructing a gastric adenocarcinoma model.

[0004] The second aspect of the present invention aims to provide a method for preparing gastric adenocarcinoma cells.

[0005] The third aspect of the present invention aims to provide a gastric adenocarcinoma cell.

[0006] The fourth aspect of the present invention aims to provide a method for constructing an animal model of gastric adenocarcinoma.

[0007] The purpose of the fifth aspect of the present invention is to provide the use of the gastric adenocarcinoma model or its progeny obtained by the construction method of the first aspect of the present invention, the gastric adenocarcinoma cells of the third aspect of the present invention, and the gastric adenocarcinoma animal model or its progeny obtained by the construction method of the fourth aspect of the present invention.

[0008] In order to achieve the above object, the technical solution adopted by the present invention is: The first aspect of the present invention provides a method for constructing a gastric adenocarcinoma model, comprising the following steps: breeding Anxa10-Cre / + animals or their offspring with LSL-KrasG12D / +;Tp53 R172H / + animals or their offspring to obtain LSL-KrasG12D / +;Tp53 R172H / +;Anxa10-Cre / + animals.

[0009] In some embodiments, the method comprises the following steps: breeding the offspring of Anxa10-Cre / + animals with the offspring of LSL-KrasG12D / +;Tp53 R172H / + animals to obtain LSL-KrasG12D / +;Tp53 R172H / +;Anxa10-Cre / + animals.

[0010] In some embodiments, the method for constructing the LSL-KrasG12D / +;Tp53 R172H / + animal comprises the following steps: breeding the LSL-KrasG12D / + animal or its offspring with the Tp53 R172H / + animal or its offspring to obtain the LSL-KrasG12D / +;Tp53 R172H / + animal.

[0011] In some embodiments, the method for constructing the LSL-KrasG12D / +;Tp53 R172H / + animal comprises the following steps: breeding the offspring of the LSL-KrasG12D / + animal with the offspring of the Tp53 R172H / + animal to obtain the LSL-KrasG12D / +;Tp53 R172H / + animal.

[0012] In some embodiments, the method for constructing offspring of the Anxa10-Cre / + animal comprises the following steps: breeding the Anxa10-Cre / + animal with a wild-type animal to obtain offspring of the Anxa10-Cre / + animal.

[0013] In some embodiments, the method for constructing offspring of the LSL-KrasG12D / +;Tp53 R172H / + animal comprises the following steps: breeding LSL-KrasG12D / +;Tp53 R172H / + animals with wild-type animals to obtain offspring of the LSL-KrasG12D / +;Tp53 R172H / + animal.

[0014] In some embodiments, the method for constructing offspring of the LSL-KrasG12D / + animal comprises the following steps: breeding the LSL-KrasG12D / + animal with a wild-type animal to obtain offspring of the LSL-KrasG12D / + animal.

[0015] In some embodiments, the method for constructing offspring of the Tp53 R172H / + animal comprises the following steps: breeding the Tp53 R172H / + animal with a wild-type animal to obtain offspring of the Tp53 R172H / + animal.

[0016] In some embodiments, the Anxa10-Cre / + animal is an Anxa10-CreERT2 / + animal.

[0017] In some embodiments, the construction method further comprises the following step: administering N-methyl-N-nitrosourea to the LSL-KrasG12D / +;Tp53R172H / +;Anxa10-Cre / + animal.

[0018] In some embodiments, the N-methyl-N-nitrosourea is administered via drinking water (preferably free access to drinking water).

[0019] In some embodiments, the N-methyl-N-nitrosourea is administered 2-7 days a week for 8-18 weeks; further administered 2-4 days a week for 8-10 weeks; and further administered 3 days a week for 8 weeks.

[0020] In some embodiments, the construction method further comprises the following step: administering a gene knockout activator to the LSL-KrasG12D / +;Tp53R172H / +;Anxa10-Cre / + animal.

[0021] In some embodiments, administration of the gene knockout activator is performed before administration of N-methyl-N-nitrosourea, ie, the gene knockout activator is administered first, followed by administration of N-methyl-N-nitrosourea.

[0022] In some embodiments, the gene knockout activator is tamoxifen.

[0023] In some embodiments, the gene knockout activator is administered for 4-6 days.

[0024] In some embodiments, the gene knockout activator is administered in an amount of 50-100 mg / kg.d.

[0025] In some embodiments, the gene knockout activator is administered by injection (preferably intraperitoneal injection).

[0026] The second aspect of the present invention provides a method for preparing gastric adenocarcinoma cells, comprising the following steps: isolating gastric gland tumor tissue from the gastric adenocarcinoma model or its progeny obtained by the construction method of the first aspect of the present invention and culturing the tissue in vitro to obtain gastric adenocarcinoma cells.

[0027] In some embodiments, the preparation method further comprises the following step: immortalizing the gastric adenocarcinoma cells.

[0028] In some embodiments, the immortalization method comprises the following step: infecting the gastric adenocarcinoma cells with an SV40 overexpression virus (preferably a lentivirus).

[0029] The third aspect of the present invention provides a gastric adenocarcinoma cell, which is obtained by the preparation method of the second aspect of the present invention.

[0030] A gastric adenocarcinoma cell line, the gastric adenocarcinoma cell line is named ST-YC19, classified as a mouse gastric adenocarcinoma cell line, and deposited on April 3, 2025, at the General Microbiology Center of the China Culture Collection Administration, with the deposit number CGMCC No. 46342. The deposit address is the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0031] A fourth aspect of the present invention provides a method for constructing an animal model of gastric adenocarcinoma, comprising inoculating the gastric adenocarcinoma cells of the third aspect of the present invention into an animal.

[0032] In some embodiments, the vaccination is by injection, for example, in situ injection, intravenous injection, intraperitoneal injection, subcutaneous injection, intradermal injection or intramuscular injection.

[0033] The fifth aspect of the present invention provides any application of a1) to a2): a1) Use of the gastric adenocarcinoma cells according to the third aspect of the present invention in any one of b1) to b6): b1) Establishing an animal model of gastric adenocarcinoma; b2) screening for drugs for preventing and / or treating gastric adenocarcinoma; b3) Research on the pathogenesis, development and / or metastasis of gastric adenocarcinoma; b4) constructing a gastric adenocarcinoma cell model; b5) Screening for biomarkers, diagnostic and / or therapeutic targets related to gastric adenocarcinoma; b6) preparing a product for use in any one of b1) to b5); a2) Use of the gastric adenocarcinoma model or its progeny obtained by the construction method of the first aspect of the present invention, and / or the gastric adenocarcinoma animal model or its progeny obtained by the construction method of the fourth aspect of the present invention in any one of b2) to b6): b2) screening for drugs for preventing and / or treating gastric adenocarcinoma; b3) Research on the pathogenesis, development and / or metastasis of gastric adenocarcinoma; b4) constructing a gastric adenocarcinoma cell model; b5) Screening for biomarkers, diagnostic and / or therapeutic targets related to gastric adenocarcinoma; b6) preparing a product for use in any one of b2) to b5).

[0034] In some embodiments, the product comprises a reagent or a kit.

[0035] In some embodiments, the application does not involve the diagnosis or treatment of a disease.

[0036] In the present invention, the animal is a non-human animal.

[0037] In some embodiments, the non-human animal comprises a non-human mammal; further comprises at least one of a non-human primate, a rodent, a bovine (e.g., cow, bull, buffalo), a deer, a pig, a sheep (e.g., sheep, goat), a dog, a rabbit, a chicken, a cat, a ferret, a horse; and further is a rodent.

[0038] In some embodiments, the non-human primate comprises at least one of an orangutan, an ape, or a monkey (eg, a marmoset, a rhesus monkey).

[0039] In some embodiments, the rodent comprises at least one of a mouse, a rat, a hamster, and a guinea pig; further comprises at least one of a mouse and a rat.

[0040] In some embodiments, the rodent is selected from the family Muridae; further selected from the families Cricetidae (e.g., mouse-like hamsters), Cricetidae (e.g., hamsters, New World rats and mice, voles), Muroidea (true mice and rats, gerbils, spiny rats, crested rats), Malmyridae (climbing mice, rock mice, tailed rats, Madagascar rats, and mice), Spinellidae (e.g., spiny dormouse), and Mormoriidae (e.g., mole rats, bamboo rats, and zokors).

[0041] In some embodiments, the rodent is a mouse of the C57BL strain selected from the group consisting of C57BL / a, C57BL / An, C57BL / GrFa, C57BL / KaLwN, C57BL6, C57BL / 10, C57BL10ScSn, C57BL / 10Cr, and C57BL / Ola. In some embodiments, the mouse is a 129 strain selected from the group consisting of 129 / J, 129 / ReJ, 129 / OlaHsd, 129 / Sv, 129 / SvJ, 129 / Re, 129 / RrJ, and 129 / Sv-ter / +. These mice are described, for example, in Festing et al., Revised nomenclature for strain 129 mice, Mammalian Genome 10: 836 (1999); Auerbach et al., Establishment and Chimera Analysis of 129 / SvEv- and C57BL / 6-Derived Mouse Embryonic Stem Cell Lines (2000), the relevant contents of which are incorporated herein by reference in their entirety. In some embodiments, the mouse is a hybrid of the 129 strain and the C57BL / 6 strain. In some embodiments, the mouse is a hybrid of the 129 strain or a hybrid of the BL / 6 strain. In some embodiments, the mouse is a BALB strain, such as the BALB / c strain. In some embodiments, the mouse is a hybrid of the BALB strain and another strain. In some embodiments, the mouse is from a hybrid strain (e.g., 50% BALB / c-50% 12954 / Sv; or 50% C57BL / 6-50% 129). In some embodiments, the non-human animal is a rodent. In some embodiments, the non-human animal is a mouse having a BALB / c, BALB / cHeAn, BALB / cJ, BALB / cR1, BALB / cWt, C57BL / 10, C57BL / 10ScSn, C57BL (C57BL / 10Cr and C57BL / Ola), C58, CBA / Br, CBA / Ca, CBA / J, CBA / st, or CBA / H strain, and a mouse on a NOD, NOD / SCID, or NOD-Prkdcscid IL-2rgnull background.

[0042] In the present invention, LSL-KrasG12D / + animals represent heterozygous animals with KrasG12D mutant and wild type; similarly, Tp53 R172H / + animals represent heterozygous animals with Tp53 R172H mutant and wild type; Anxa10-Cre / + animals represent heterozygous animals with mutant (Anxa10-Cre inserted) and wild type; LSL-KrasG12D / +;Tp53 R172H / + animals represent heterozygous animals with KrasG12D mutant and wild type, and Tp53 R172H mutant and wild type; LSL-KrasG12D / +;Tp53 R172H / +;Anxa10-Cre / + animals represent heterozygous animals with KrasG12D mutant and wild type, and Tp53 Heterozygous animals for R172H mutant and wild type, and mutant (with Anxa10-Cre inserted) and wild type.

[0043] In the present invention, the reproduction is mating.

[0044] In the present invention, the gastric adenocarcinoma cells include progeny cells thereof.

[0045] The beneficial effects of the present invention are: The present invention provides a method for constructing a gastric adenocarcinoma model, comprising the following steps: breeding Anxa10-Cre / + animals or their offspring with LSL-KrasG12D / +;Tp53 R172H / + animals or their offspring to obtain LSL-KrasG12D / +;Tp53 R172H / +;Anxa10-Cre / + animals, wherein the pathological type of the gastric adenocarcinoma model obtained by the method is determined to be adenocarcinoma.

[0046] Furthermore, the construction method also includes the step of administering N-methyl-N-nitrosourea, thereby further shortening the tumor formation period (about 2.5 months) and increasing the tumor formation rate (21 / 21, or 100%).

[0047] The present invention provides a gastric adenocarcinoma cell, which can form a tumor in vivo and is an adenocarcinoma cell. At the same time, the cell has strong proliferation ability, invasion and / or migration ability. BRIEF DESCRIPTION OF THE DRAWINGS

[0048] Figure 1 Schematic diagram showing the method for constructing mice with the genotype of Kras G12D / +; Tp53 R172H / +; Anxa10-CreERT2 / +.

[0049] Figure 2The figure shows that mice with the genotype of Kras G12D / +; Tp53 R172H / +; Anxa10-CreERT2 / + were successfully constructed: A shows the results of mouse tail DNA electrophoresis gel identification of mouse Kras and Anxa10 genotypes; B shows the results of first-generation sequencing identification of mouse Tp53 and Kras genotypes.

[0050] Figure 3 The figure shows that the gastric adenocarcinoma mouse model was successfully induced: A shows a schematic diagram of the gastric adenocarcinoma mouse model induction process; B shows the anatomical diagram of mouse carcinoma in situ (yellow arrow); C shows CT imaging confirming the occurrence of gastric carcinoma in situ in mice; D shows 18F-FDG-PET imaging confirming the occurrence of gastric carcinoma in situ in mice.

[0051] Figure 4 The figure shows the induced gastric orthotopic tumor model in mice, which is adenocarcinoma. The scale bar is 100 µm.

[0052] Figure 5 Shown are images of immunofluorescence staining of primary cells, with a scale bar of 100 µm.

[0053] Figure 6 It shows that ST-YC19 can form tumors in mice, and the tumors are adenocarcinomas. The scale bar is 100 μm.

[0054] Figure 7 The malignant phenotypes of ST-YC19 and common gastric cancer cells are shown: A shows the brightfield cell morphology of ST-YC19, with a scale bar of 100 µm; B shows the migration and invasion abilities of ST-YC19, the human gastric adenocarcinoma cell line HGC-27, and the mouse gastric squamous cell carcinoma line MFC, with a scale bar of 200 µm; C shows the proliferation abilities of ST-YC19, the human gastric adenocarcinoma cell line HGC-27, the mouse gastric squamous cell carcinoma line MFC, and normal mouse gastric epithelial cells (**** indicates p less than 0.0001 compared with ST-YC19). DETAILED DESCRIPTION

[0055] The present invention is further described in detail below through specific examples.

[0056] It should be understood that these examples are only used to illustrate the present invention and are not used to limit the scope of the present invention.

[0057] the term Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as commonly used in the field to which the present invention belongs. For the purpose of interpreting this specification, the following definitions will apply, and where appropriate, terms used in the singular will also include the plural form, and vice versa.

[0058] As used herein, the term "about" refers to a range of ±20% of the value that follows. In some embodiments, the term "about" refers to a range of ±10% of the value that follows. In some embodiments, the term "about" refers to a range of ±5% of the value that follows.

[0059] Experimental procedures in the following examples, where specific conditions are not specified, generally followed conventional conditions or those recommended by the manufacturer. Materials and reagents used in these examples were commercially available unless otherwise specified. Where the manufacturer of the reagent is indicated, similar products from other manufacturers are considered substitutes. Example

[0060] 1. Establishment of a Mouse Gastric Adenocarcinoma Model The inventors discovered the key gene mutations in the occurrence of gastric adenocarcinoma: TP53 mutation and RTK-KRAS pathway activation are the most critical changes in gastric adenocarcinoma, and are characteristic mutations of chromosomal instability (CIN) gastric adenocarcinoma, the most common molecular subtype of gastric cancer. TP53 (Trp53) and KRAS mutations are key events driving the malignant transformation of cells, enabling cells to proliferate rapidly and without restriction. Annexin A10 (ANXA10) belongs to the annexin (ANX) family and is specifically expressed in the gastric mucosa, but not in other normal organs. Therefore, the LSL-KrasG12D / +Tp53R172H / + allele and Anxa10-CreERT2 / + mice were first constructed to achieve that under the induction of tamoxifen, KrasG12D / + can specifically occur in the gastric mucosa of mice. Specific operational details: (1) Construction of Anxa10-CreERT2 / + mice: C57BL / 6Smoc- Anxa10 em1(2A-CreERT2-Wpre-pA)Smoc Mice (purchased from Shanghai Model Organisms, catalog number NM-KI-200312) were mated with C57BL / 6J mice to obtain positive offspring mice, namely Anxa10-CreERT2 / + mice (Anxa10 CreERT2 mice).

[0061] (2) Construction of Tp53R172H / + (Tp53em4) mice: C57BL / 6Smoc- Trp53 em4(R172H)Smoc Mice (purchased from Shanghai Model Organisms, catalog number NM-KI-18028) were mated with C57BL / 6J mice to obtain positive offspring mice, namely Tp53R172H / + (Tp53em4) mice (P53 R172H mice).

[0062] (3) Construction of LSL-KrasG12D / + (Krasem4) mice: C57BL / 6Smoc- Kras em4(LSL-G12D)Smoc Mice (purchased from Shanghai Model Organisms, catalog number NM-KI-190003) were mated with C57BL / 6J mice to obtain positive offspring mice, namely LSL-KrasG12D / + (Krasem4) mice (LSL-Kras G12D mice).

[0063] (4) Construction of mice with the genotype of Kras G12D / +; Tp53 R172H / +; Anxa10-CreERT2 / +: Schematic diagram of the construction method of mice with the genotype of Kras G12D / +; Tp53 R172H / +; Anxa10-CreERT2 / + is shown in Figure 1 As shown, the specific details are as follows: Tp53R172H / + (Tp53em4) mice (P53 R172H mice) and LSL-KrasG12D / +(Krasem4) mice (LSL-Kras G12D The obtained mice (LSL-Kras) were crossed with KrasG12D / + (Krasem4) and Tp53R172H / + (Tp53em4) alleles. G12D ;P53 R172H mice) and Anxa10-CreERT2 / + mice (Anxa10 CreERT2 The offspring were screened to obtain mice with the genotype of Kras G12D / +; Tp53 R172H / +; Anxa10-CreERT2 / +.

[0064] The method for screening and obtaining mice with the genotype of Kras G12D / +; Tp53 R172H / +; Anxa10-CreERT2 / + from the hybrid offspring is as follows: DNA was extracted from the tail tissue of the hybrid offspring mice using a DNA extraction kit (TIANGEN, Beijing, China). The primer sequences for genotyping identification of transgenic mice are shown in Tables 1 and 2. PCR amplification was performed using 2x TransFast TaqPCR SuperMix (TransGen, Beijing, China). The thermal cycling conditions included pre-denaturation at 94°C for 3 minutes, followed by 35 cycles, each cycle consisting of denaturation at 95°C for 5 seconds, annealing at 60°C for 15 seconds, and extension at 72°C for 35 seconds. The final extension was at 72°C for 5 minutes. PCR products were separated on a 1.2% agarose gel and visualized with a nucleic acid stain (Gene-Protein Link, Beijing, China) to identify the mouse KRAS and Anax10 genotypes. At the same time, the P53 and KRAS genotypes were identified by first-generation sequencing, and the results are shown in Figure 2. Figure 2 As shown: Mice with the genotype of Kras G12D / +; Tp53 R172H / +; Anxa10-CreERT2 / + were screened and obtained.

[0065] Table 1 PCR primers used for genotyping of KrasG12D and Anxa10-CreERT2 Gene Primers sequence KrasG12D Universal (forward primer) 5′-CTGCATAGTACGCTATACCCTGT-3′, SEQ ID NO:1 Wild type (reverse primer) 5′-TGTCTTTCCCCAGCACAGT-3′, SEQ ID NO: 2 Mutant type (reverse primer) 5′-GCAGGTCGAGGGACCTAATA-3′, SEQ ID NO:3 Anxa10-CreERT2 Universal (forward primer) 5′-ATCTCCCCATCCTCCCTAACTT-3′, SEQ ID NO:4 Wild type (reverse primer) 5′-ATCGCATCACCTTCAAACTCT-3′, SEQ ID NO:5 Mutant type (reverse primer) 5′-AGCCCGGACCGACGATGAAGC-3′, SEQ ID NO:6 Table 2 Sequencing primers used for KrasG12D and Tp53R172H genotyping Gene Primers sequence KrasG12D Forward primer 5′-CCATTAGCTGCTACAAACA-3′, SEQ ID NO:7 Reverse primer 5′-CTCTATCGTAGGGTCGTACT-3′, SEQ ID NO:8 Tp53R172H Forward primer 5′-GAGGGCGTCCAATGGTGCTT-3′, SEQ ID NO:9 Reverse primer 5′-CTAGGCTGGAGTCAACTGTC-3′, SEQ ID NO:10 (5) Induced gastric adenocarcinoma mouse model: Schematic diagram of the induction process of gastric adenocarcinoma mouse model Figure 3 As shown in A, the details are as follows: Six- to eight-week-old Kras G12D / +; Tp53 R172H / +; Anxa10-CreERT2 / + mice were transferred to the Laboratory Animal Center of Peking University Cancer Hospital and housed in a specific pathogen-free environment. The facility maintained a 12-h light / dark cycle at 24°C. The mice were provided with sterile food, water, and bedding. Tamoxifen (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in corn oil (Aladdin, Shanghai, China) at a concentration of 20 mg / ml and shaken overnight at 37°C. The dissolved tamoxifen solution was stored at 4°C during injection. Tamoxifen was administered intraperitoneally once daily for 5 days (days 1 to 5) based on mouse body weight at a dose of 75 mg / kg. Before each injection, the injection site was disinfected with 70% ethanol. Experimental procedures followed protocols approved by the Ethics Committee of Peking University Cancer Hospital.

[0066] After tamoxifen administration (i.e., on day 6), N-methyl-N-nitrosourea (MNU) was used as a co-inducing agent. The specific method was as follows: MNU solution was placed in a light-proof bottle as long-term drinking water for mice for 3 days each week (specifically, Monday, Wednesday, and Friday), and the mice were allowed to drink freely for 8 consecutive weeks. MNU solution (Aladdin, Shanghai, China) was freshly prepared with distilled water and used immediately, with a concentration of 120 ppm. During the tamoxifen injection, MNU administration, and observation period, the mice were carefully monitored to observe whether tumors formed and any adverse reactions. After 8 weeks of MNU treatment, a mass was palpable in the upper left abdomen of the mice, and 18F-FDG-PET / CT was used to confirm the presence of in situ tumors in the mice ( Figure 3 C and D in the middle), gastric in situ tumors were found after the mice were dissected ( Figure 3 Middle B), identified as gastric adenocarcinoma by HE staining ( Figure 4 ), namely, gastric adenocarcinoma in situ occurs in mice.

[0067] It can be seen that the tumor formation period of the mouse gastric adenocarcinoma model provided by the present invention is shortened (about 2.5 months), which is lower than that of other model construction methods: 13 months (MNU, Cancer Letters. 2002 May 28;179(2):121-32); 12 months (Tp53 R270H / + combined with MNU, Nature Genetics. 2020 Feb 5;52(2):219–230); 5 months (Tp53R172H / +; KrasG12D / +, Gastroenterology. 2023 Feb 4;164(7):1119–1136.e12); and the tumor formation rate is significantly improved (21 / 21, i.e. 100%); higher than that of other model construction methods: 31.8% (MNU, Cancer Letters. 2002 May 28;179(2):121-32); 63% (Tp53 R270H / + combined with MNU, Nature Genetics. 2020 Feb5;52(2):219–230).

[0068] 2. Construction of an Immortalized Mouse Gastric Adenocarcinoma Cell Line Capable of In Vivo Tumorigenesis After 18F-FDG-PET / CT imaging confirmed the in situ formation of tumors in mice, the mice were killed by cervical dislocation and disinfected by soaking in 75% alcohol. The mice were dissected on a sterile operating table, and the tumors were removed. A portion was fixed with 4% paraformaldehyde and embedded. The pathological type of tumor tissue was identified by HE staining. The results are as follows: Figure 4 Shown: The induced mouse gastric in situ tumor model is adenocarcinoma; a part is cut into 1mm 3 Small pieces were implanted subcutaneously in C57 mice. When the tumor grew to 500 mm 3 At 1 hr, mice were killed by cervical dislocation. Tumor tissue was removed under a sterile operating table, placed in phosphate-buffered saline (PBS), and washed twice. Any connective tissue was carefully removed. A portion of the tissue was fixed with 4% paraformaldehyde and embedded. The pathological type of the tumor tissue was identified by HE staining. The other portion of the tumor tissue was cut into small pieces of approximately 1 mm³ and washed twice with PBS. 1% type IV collagenase was added, gently mixed with a pipette, and incubated in a shaking water bath at 37°C for 1 hour. Digestion was terminated by adding two volumes of complete medium containing 10% fetal bovine serum (FBS). The sample was centrifuged at 1000 rpm for 5 minutes, and the supernatant was discarded. The cells were resuspended in epithelial cell-specific complete medium to prepare a cell suspension. The suspension was diluted to 2 × 10 5Cells were seeded at a density of 10 cells / ml into T25 culture flasks coated with Matrigel, with 5 ml per flask. The culture flasks were incubated at 37°C in a 5% CO2 environment, and the culture medium was changed every 2-3 days. Once the cells reached >80% confluency, they were subcultured; the immunofluorescence staining results of primary cells were as follows: Figure 5 As shown: The cells express CK-19, which means they are gastric adenocarcinoma cells. To achieve cell immortalization, the cells were transfected with SV40 overexpression lentivirus: the cells were seeded in 6-well plates, with approximately 1×10 cells per well. 5 cells. The next day, after the cells adhered to the wall, the culture medium was replaced. Then 1 mL of complete culture medium and 20 μL of SV40 overexpression lentivirus (Mason cell CTCC-DZ-0120, infection concentration MOI=10) were added and mixed gently. Incubate the cells. After 12 hours, check the cell status and replace the culture medium with fresh complete culture medium. When the cells reach confluence at the bottom of the well, they are passaged into a T25 culture flask. After continuing to passage 6, it was determined that the cell line was established and named ST-YC19. It was classified and named as the mouse gastric adenocarcinoma cell line, and was deposited in the General Microbiology Center of the China Microorganism Culture Collection Administration on April 3, 2025. The deposit number is CGMCC No. 46342, and the deposit address is the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The bright field image of ST-YC19 is shown below. Figure 7 As shown in A.

[0069] To verify that ST-YC19 can form tumors in mice, ST-YC19 cells were cultured in vitro, counted, and resuspended in PBS solution. 6 The cells were injected into the flank of mice at a dose of 10 cells / mouse. The tumor formation was observed regularly. The tumor mass grew to 500 mm. 3 HE test was then performed to observe the pathological type. Figure 6 As shown: ST-YC19 can form tumors in mice, and the tumors are adenocarcinomas.

[0070] 3. Comparison of the malignant phenotypes of the mouse gastric adenocarcinoma immortalized cell line ST-YC19 and common gastric cancer cells The CCK-8 assay (Tongren, Japan) was used to compare ST-YC19 (experimental group), human gastric adenocarcinoma cell line (human gastric cancer cell line, HGC-27, purchased from the National Laboratory Cell Resource Sharing Service Platform, No. 3101HUMTCHu22, control group), mouse gastric squamous cell carcinoma cell line (mouse forestomach carcinoma cell line, MFC, purchased from the National Laboratory Cell Resource Sharing Service Platform, No. 1101MOU-PUMC000143, control group), mouse gastric normal epithelial cells (mouse gastric mucosal epithelial cells, Epithelial, purchased from Shanghai The proliferation rate of proliferating cells (ST-YC19, HGC-27, MFC, and Epithelial) was measured as follows: Six replicate wells were prepared for each group, with time points set at 24, 48, 72, and 96 hours. The total cell number and total volume of culture medium were calculated based on the requirement of 3,000 cells and 100 μL of culture medium per well. A cell suspension was prepared in a centrifuge tube and gently pipetted to mix thoroughly. The cell suspension was transferred to a sample reservoir. 100 μL of the cell suspension was pipetted into each well of a 96-well plate and evenly and quickly dispensed into the center of each well. 100 μL of PBS was added to the remaining wells. The cells were incubated at 37°C. After 8 hours, the cell adhesion was observed under a microscope. When most of the cells had adhered, the CCK-8 reagent was diluted with serum-free culture medium (1 mL culture medium with 100 μL CCK-8); the culture medium in the 96-well plate was removed and 100 μL of diluted CCK-8 was added, and then the plate was placed in a cell culture incubator and incubated for 1 hour. The absorbance value was measured at 450 nm using a microplate reader. At the same time, the cell status at other time points was regularly observed using a microscope and the culture medium was replaced. The absorbance was measured using a microplate reader as planned. The cell proliferation curve at each time point was drawn using Graphpad Prism 8.0 software. The results are shown in Figure 2. Figure 7 As shown in C: The proliferation ability of ST-YC19 is significantly better than that of human gastric adenocarcinoma cell line HGC-27, mouse gastric squamous cell carcinoma cell line (MFC), and mouse normal gastric epithelial cells (Epithelial).

[0071] Transwell technique was used to compare the migration and invasion abilities of the ST-YC19 (experimental group), human gastric adenocarcinoma cell line HGC-27 (control group), and mouse gastric squamous cell carcinoma cell line (control group), as follows: Migration experiment: Place the Transwell chamber in a 24-well culture plate, add 200 μL and 500 μL of serum-free medium to the upper chamber and lower chamber respectively, then place the culture plate in an incubator for 30 minutes to balance and then aspirate the equilibration medium. Use trypsin to digest the cells and centrifuge them. Then resuspend the cells in serum-free medium and count them using a cell counting plate. Establish experimental and control groups, and set the groups at the following time points: 24 hours, with three chambers set at each time point. According to the cell density required for each chamber of 5×10 4 Calculate the total number of cells required and the total volume of serum-free medium with 200 μL of serum-free medium per chamber. Prepare a cell suspension in a centrifuge tube and mix gently by pipetting. Add 500 μL of complete medium to the lower chamber and slowly add 200 μL of cell suspension to the upper chamber. Incubate in a 37°C incubator. Remove the chamber at the corresponding time point of 24 hours, wash it lightly with PBS, and fix it with ice-cold methanol for 10 minutes; wash it lightly with PBS again and let it dry, add crystal violet stain for 5 minutes, wash off the crystal violet with PBS, and let it dry. Carefully cut the membrane with a blade, place it on a slide, and seal it with sealing glue. Take pictures after drying. Select 3 fields of view in each chamber to take pictures. Use Image J software to count the number of migrated cells, and use Graphpad software to draw a bar graph.

[0072] Invasion assay: Dilute Matrigel 1:8 with PBS buffer. Take 60 μL of diluted Matrigel and quickly and evenly spread it on the upper chamber surface at the bottom of the Transwell chamber. Place the Transwell chamber in a 37°C incubator overnight to allow the matrix gel to solidify into a thin film. The next day, aspirate the liquid in the upper chamber and add 100 μL of serum-free culture medium to each well. Place the Transwell chamber back in the incubator and continue to place it for 30 minutes to allow the basement membrane to hydrate. The remaining steps are the same as the cell migration experiment, the only difference being that the cell density required for each chamber is 8×10 4 .

[0073] The results are as follows Figure 7 As shown in B: The migration ability of ST-YC19 is significantly better than that of the human gastric adenocarcinoma cell line HGC-27 and the mouse gastric squamous cell carcinoma cell line. The invasion ability of ST-YC19 is significantly better than that of the mouse gastric squamous cell carcinoma cell line. Although the invasion ability of ST-YC19 is not significantly better than that of the human gastric adenocarcinoma cell line HGC-27, it is still better than that of the mouse gastric squamous cell carcinoma cell line.

[0074] The technical solution of the present invention is not limited to the above-mentioned specific embodiments. Any technical variations made according to the technical solution of the present invention fall within the protection scope of the present invention.

Claims

1. A method for constructing a gastric adenocarcinoma model, comprising the following steps: Anxa10-Cre / + animals or their offspring were bred with LSL-KrasG12D / +;Tp53 R172H / + animals or their offspring to obtain LSL-KrasG12D / +;Tp53 R172H / +;Anxa10-Cre / + animals; N-methyl-N-nitrosourea was administered to LSL-KrasG12D / +;Tp53 R172H / +;Anxa10-Cre / + animals.

2. The construction method according to claim 1, characterized in that The method for constructing the LSL-KrasG12D / +;Tp53 R172H / + animal comprises the following steps: breeding the LSL-KrasG12D / + animal or its offspring with the Tp53 R172H / + animal or its offspring to obtain the LSL-KrasG12D / +;Tp53R172H / + animal; and / or The construction method further comprises the following step: administering a gene knockout activator to the LSL-KrasG12D / +;Tp53 R172H / +;Anxa10-Cre / + animal.

3. The construction method according to claim 2, characterized in that The gene knockout activator is tamoxifen.

4. A method for preparing gastric adenocarcinoma cells, comprising the steps of isolating gastric tumor tissue from the gastric adenocarcinoma model or its progeny obtained by the construction method of any one of claims 1 to 3 and culturing the tissue in vitro to obtain gastric adenocarcinoma cells.

5. The preparation method according to claim 4, characterized in that The preparation method further comprises the following step: performing immortalization treatment on the gastric adenocarcinoma cells.

6. A gastric adenocarcinoma cell, obtained by the preparation method according to any one of claims 4 to 5.

7. The gastric adenocarcinoma cell according to claim 6, characterized in that The gastric adenocarcinoma cell line is named ST-YC19 and is classified as a mouse gastric adenocarcinoma cell line. It was deposited in the General Microbiology Center of the China Culture Collection Administration on April 3, 2025, with the deposit number CGMCC No. 46342. The deposit address is the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

8. A method for constructing an animal model of gastric adenocarcinoma, comprising inoculating the gastric adenocarcinoma cells according to any one of claims 6 to 7 into an animal.

9. The construction method according to claim 8, characterized in that: The vaccination method is injection.

10. Use of the gastric adenocarcinoma cell according to any one of claims 6 to 7 in any one of b1) to b6): b1) Establishing an animal model of gastric adenocarcinoma; b2) screening for drugs for preventing and / or treating gastric adenocarcinoma; b3) Study the pathogenesis, development and / or metastasis of gastric adenocarcinoma; b4) constructing a gastric adenocarcinoma cell model; b5) Screening for biomarkers, diagnostic and / or therapeutic targets related to gastric adenocarcinoma; b6) preparing a product for use in any one of b1) to b5).

11. Use of the gastric adenocarcinoma model or its progeny obtained by the construction method according to any one of claims 1 to 3, and / or the gastric adenocarcinoma animal model or its progeny obtained by the construction method according to any one of claims 8 to 9, in any one of items b2) to b6): b2) screening for drugs for preventing and / or treating gastric adenocarcinoma; b3) Study the pathogenesis, development and / or metastasis of gastric adenocarcinoma; b4) constructing a gastric adenocarcinoma cell model; b5) Screening for biomarkers, diagnostic and / or therapeutic targets related to gastric adenocarcinoma; b6) preparing a product for use in any one of b2) to b5); The applications described in b2), b3) and b5) do not involve the diagnosis or treatment of diseases.

12. The construction method, preparation method, gastric adenocarcinoma cell, or use according to any one of claims 1 to 11, characterized in that: The animal is a rodent.

Citation Information

Patent Citations

  • IL-15 humanized mouse model and application thereof

    CN114786479A

  • Construction method and application of gastric adenocarcinoma transgenic mouse model

    CN119174414A

  • Construction method and application of mouse gastric cancer spontaneous tumor model

    CN119498254A

  • Establishment method and application of mouse gastric cancer orthotopic transplantation model

    CN119564369A

  • de novo CARCINOGENIC PANCREATIC CANCER CELL STRAIN

    JP2013212080A